Artiva Biotherapeutics, Inc

Viking Therapeutics, Inc. is a biotechnology company based in San Diego, CA, focused on developing novel therapeutics for patients with metabolic and endocrine disorders. Their pipeline includes several drug candidates targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare diseases like X-linked adrenoleukodystrophy (X-ALD). The company's key candidates include VK2735 for obesity disorders, VK2809 for NASH, and VK5211 aimed at hip fracture muscle wasting. Viking Therapeutics is committed to advancing innovative treatments that promise to improve patient outcomes in metabolic health. Generated from the website

Plex Pharmaceuticals, Inc., based in San Diego, CA, is a scientifically-driven company focused on enhancing the lives of patients with complex diseases, particularly neurodegenerative disorders such as Parkinson's disease and glioblastoma. Their innovative drug discovery programs target misfolded proteins and employ cutting-edge technologies to develop therapies that address these pressing health challenges. In addition to their neurodegenerative research, Plex is working on non-surgical treatments for cataracts, which contribute significantly to global blindness, and has initiated efforts to develop inhibitors for CNS refractory tumors. By employing a unique fragment-based drug discovery approach, Plex aims to expedite the identification of new chemical entities that exhibit potential therapeutic efficacy. Generated from the website

Nile Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing products for the treatment of cardiovascular diseases. Its compound, CD-NP, is a chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure. The company is also developing CU-NP, which is a chimeric natriuretic peptide in preclinical development.